First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

Prime and target immunization protects against liver-stage malaria in mice

(2018) Anita Gola et al.   Science Translational Medicine

Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial

(2017) Mahamadou S Sissoko et al.   LANCET INFECTIOUS DISEASES

Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants

(2017) Carly M. Bliss et al.   MOLECULAR THERAPY

The prevalence of Plasmodium falciparum in sub-Saharan Africa since 1900

(2017) Robert W. Snow et al.   NATURE

Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial

(2017) Victorine A. Mensah et al.   Frontiers in Immunology

The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination

(2016) Pascale Vandoolaeghe et al.   Expert Review of Vaccines

Implementation of the malaria candidate vaccine RTS,S/AS01

(2016) Brian Greenwood et al.   LANCET

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants

(2016) Muhammed O Afolabi et al.   MOLECULAR THERAPY

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal

(2016) Victorine A. Mensah et al.   PLoS One

Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults

(2015) Caroline Ogwang et al.   Science Translational Medicine

Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors

(2014) Issa Nébié et al.   Clinical and Vaccine Immunology

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals

(2014) Susanne H. Hodgson et al.   JOURNAL OF INFECTIOUS DISEASES

Malaria Incidence in Children in South-West Burkina Faso: Comparison of Active and Passive Case Detection Methods

(2014) Alfred B. Tiono et al.   PLoS One

Plasmodium falciparum Malaria in Children Aged 0-2 Years: The Role of Foetal Haemoglobin and Maternal Antibodies to Two Asexual Malaria Vaccine Candidates (MSP3 and GLURP)

(2014) David Tiga Kangoye et al.   PLoS One

Malaria vaccine technology roadmap

(2013) Vasee S Moorthy et al.   LANCET

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation

(2013) Katie J. Ewer et al.   Nature Communications

Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector

(2012) Geraldine A. O’Hara et al.   JOURNAL OF INFECTIOUS DISEASES

Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors

(2011) Susanne H Sheehy et al.   MOLECULAR THERAPY

Association of HLA alleles with Plasmodium falciparum severity in Malian children

(2011) K. E. Lyke et al.   TISSUE ANTIGENS

Malaria elimination: worthy, challenging, and just possible

(2010) Pam Das et al.   LANCET